C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  ACS Medicinal Chemistry Letters

• Publication date

  2014-11-26

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/ml500341wPMID 25516785PMCID PMC4265826
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of 2-pyridylureas as glucokinase activators.

  2014cited by this paper
• Characterization of a Novel Glucokinase Activator in Rat and Mouse Models

  2014cited by this paper
• Identification of a new class of glucokinase activators through structure-based design.

  2013cited by this paper
• Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes

  2013cited by this paper
• Chapter 4:Glucokinase Activators in Development

  2012cited by this paper
• Kinase activators as a novel class of antidiabetic agents

  2012cited by this paper
• Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

  2011cited by this paper
• National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.

  2011cited by this paper
• Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

  2011cited by this paper
• Novel glucokinase activators: a patent review (2008 – 2010)

  2011cited by this paper
• Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.

  2010cited by this paper
• Assessing the potential of glucokinase activators in diabetes therapy

  2009cited by this paper
• Glucokinase activators for the potential treatment of type 2 diabetes.

  2008cited by this paper
• Diabetes‐associated macrovasculopathy: pathophysiology and pathogenesis

  2007cited by this paper
• Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component.

  2006cited by this paper
• Medicinal chemical properties of successful central nervous system drugs

  2005cited by this paper
• Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy

  2003cited by this paper
• Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design.

  2002cited by this paper
• Molecular properties that influence the oral bioavailability of drug candidates.

  2002cited by this paper
• A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate

  1990cited by this paper
• A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate.

  1989cited by this paper
• Cellular and Molecular Life Sciences Review Molecular Physiology of Mammalian Glucokinase

  year unknowncited by this paper

• Expanding the Synthetic Scope of Rawal's Diene: Access to Pyran and Pyrazole Derivatives.

  2026cites this paper
• Pyridine Derivatives: A Comprehensive Review of Their Potential as Anti-Diabetic Agents.

  2025cites this paper
• Cyclobutanes in Small‐Molecule Drug Candidates

  2022cites this paper
• Monoprotected Diamines Derived from 1,5‐Disubstituted (Aza)spiro[2.3]hexane Scaffolds

  2021cites this paper
• A comprehensive review on glucokinase activators: Promising agents for the treatment of Type 2 diabetes

  2021cites this paper
• Diastereoselective Synthesis of a cis-1,3-Disubstituted Cyclobutane Carboxylic Acid Scaffold for TAK-828F, a Potent Retinoic Acid Receptor-Related Orphan Receptor (ROR)-γt Inverse Agonist.

  2021cites this paper
• Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics.

  2020cites this paper
• Recent Updates on Glucokinase Activators and Glucokinase Regulatory Protein Disrupters for the Treatment of Type 2 Diabetes Mellitus.

  2019cites this paper
• Convenient entry to N-pyridinylureas with pharmaceutically privileged oxadiazole substituents via the acid-catalyzed C H activation of N-oxides

  2019cites this paper
• Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.

  2017cites this paper
• Development of a stereoselective and scalable process for the preparation of a methylcyclobutanol-pyridyl ether.

  2017cites this paper
• Novel Series of Potent Glucokinase Activators Leading to the Discovery of AM-2394.

  2016cites this paper
• Investigational insulin secretagogues for type 2 diabetes

  2016cites this paper
• Synthesis and Physicochemical Properties of 3‐Fluorocyclobutylamines

  2015cites this paper